Horizon Pharma plc, a biopharmaceutical company, has launched UCD in Common, an effort to educate people about urea cycle disorder, a rare genetic disease characterized by toxic levels of ammonia in the blood.
The initiative includes a website and Facebook page with videos and lifestyle tips, as well as low-protein recipes for people living with a UCD.
UCD affects approximately 1 in 35,000 live births in the United States, according to a Horizon Pharma press release.
"At Horizon we have a long-term commitment to helping people living with rare diseases in ways that go beyond our medicines, and we've used our resources to empower the UCD community to generate ideas and create tools that will help others living with this rare, isolating disease," Dave Happel, executive vice president of Horizon Pharma's Orphan Business Unit, said in the release. "We are grateful for the opportunity to work with such a passionate group of patients, caregivers and families whose journeys and insights led to the development of UCD in Common."
